MedTrace Logo

Dexmedetomidine for Sedation During Radiological Interventional Procedures

NCT02180737 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-04-19

No results posted yet for this study

Summary

Evaluation of the role of dexmedetomidine as a sole agent in sedating patients undergoing interventional radiological procedures and measuring its different outcome variables.

Conditions

  • Procedural Sedation

Interventions

DRUG

Dexmeditomedine

Sponsors & Collaborators

  • National Cancer Institute, Egypt

    lead OTHER

Principal Investigators

  • Wafaa T Salem, MD · National Cancer Institute (NCI)

  • Maie K Helaly, MD · National Cancer Institute (NCI)

  • Ghada M Bashandy, MD · National Cancer Institute (NCI)

  • Ayat A Hassan, MD · National Cancer Institute (NCI)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-12-31
Completion
2015-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02180737 on ClinicalTrials.gov